ELAB Elevai Labs
- 0.630
- -0.001-0.16%
- 0.643
- +0.013+2.05%
Elevai Labs News
Express News | Elevai Labs Q1 2024 Revneue $614.563K Up From $142.820K YoY
Elevai Labs 1Q Rev $614,563 >ELAB
Elevai Labs 1Q Rev $614,563 >ELAB
Express News | ELEVAI Labs Inc. Reports First Quarter 2024 Financial Results
Elevai Labs | 10-Q: Quarterly report
ELEVAI Labs Expands Portfolio and Restructures Subsidiaries
Express News | Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies Evaluating the Treatment Effect of EL-22
Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset "EL-22" For The Treatment Of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic fea
Express News | Elevai Labs Announces Launch Of Elevai Biosciences And Elevai Skincare Subsidiaries
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
GainersElevai Labs (NASDAQ:ELAB) shares rose 22.7% to $0.8 during Wednesday's after-market session. The company's market cap stands at $13.8 million. Vintage Wine Estates (NASDAQ:VWE) shares rose 4.99
Elevai Labs Expands With Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc.Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development
Express News | Elevai Labs Acquires Exclusive License To Two Myostatin Muscle Loss Prevention Assets, Announces Plan To Develop In Combination With GLP-1 Obesity Treatments
Express News | ELEVAI Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets With Plan to Develop in Combination With GLP-1 Obesity Treatments
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
Five international distribution agreements signed to dateCumulative contracted minimum purchase requirements of $4.9M in the first five yearsUp to five additional international distribution agreements in discussion
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session
GainersFarmer Bros (NASDAQ:FARM) stock increased by 4.8% to $3.48 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Pricesmart (NASDAQ:PSMT) stock moved upwards
Elevai Labs Reports Q4 Results
Elevai Labs 4Q Rev $698,591 >ELAB
Elevai Labs 4Q Rev $698,591 >ELAB
Press Release: Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results -- Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year -
ELEVAI Launches Consumer Skincare Portal
ELEVAI Labs, Inc. (NASDAQ: ELAB), known for its medical aesthetic products, has announced the launch of its online E-commerce platform, transitioning from a purely business-to-business model to also include direct-to-consumer sales.
Express News | Elevai Labs Launches Online E-Commerce Portal
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
NEWPORT BEACH, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ:ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of its online
Analysis
Price Target
No Data
